NP方案和CAP方案治疗晚期非小细胞肺癌疗效对比分析

A Clinical Study of NP in Contrast to the CAP in Treatment of Cases with advanced Non-small-cell Lung Cancer

目的 :对比性观察分析长春瑞滨 +顺铂 (NVB +DDP)方案与环磷酰胺 +阿霉素 +顺铂 (CAP)方案治疗非小细胞肺癌的临床疗效。方法 :4 8例Ⅲ～Ⅳ期NSCLC肺癌采用NVB2 5mg/m2 d1,5iv ;DDP35mg/m2 d1～ 3天联合方案及 5 6例Ⅲ～Ⅳ期NSCLC采用CAP方案。即CTX6 0 0mg/m2 d1天 ,ADM35mg/m2 d1天 ,DDP30mg/m2 d1～ 3天。结果 :NP组 :CR +PR =2 4例 ,有效率 5 0 % ,中位缓解期 5 5个月 ,中位生存期 11个月。CAP组 :CR +PR =2 0例 ,有效率 35 7% ,中位缓解期 4个月。中位生存期 8个月。主要毒副反应 :NP组为骨髓抑制及静脉炎 ,CAP组为消化道反应、脱发、心电图改变。结论 :NP组联合化疗治疗晚期NSCLC疗效较高 ,副作用可以耐受 。

Objective:A clinical study of (NVB+DDP) in contrast to the (CAP) in treatment of advanced non small cell lung cancer has been carried.Methods:48 cases with advanced NSCLC (Stage Ⅲ～Ⅳ) were treated with NP chemotherapy. The dosage of NVB was 25mg/m 2 iv.d1.5, that of DDP was 35mg/m 2,iv, d1～3. The other 56 cases with advanced NSCLC (stage Ⅲ～Ⅳ) treated with CAP chemotherapy. The dosage was CTX 600mg/m 2, d1,iv., ADM 35mg/m 2,d1,iv,DDP 30mg/m 2,iv,dvip.d1～3.Results:For the cases with NVB+DDP, the overall response rate was 50%(CR+PR=24), Medium response time was 5 5 months. Medium survival time was 11 months.For the cases with CAP, the overall response rate was 35 7%(CR+PR=20), Medium response time and survival time were 4 and 8 months respectively.Majore toxicity:For the group of NVB+DDP,myelosuppression and vein inflammation can be observed. For the other group of CAP, nausea vomiting alopecia and cardiotoxicity was associated.Conclusion:NVB plus DDP chemotherapy for advanced NSCLC shows a good curative effect and low toxicity. It deserves further clinical application.